12 mg daily from day 1 to 14 of a 21-day cycle

Recurrent Glioblastoma

Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.

Anlotinib

Shandong cancer hospital

Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib

Phase II Clinical Trials on Anlotinib for the Treatment of Recurrent Glioblastoma.

PFS defined as the time from first dose of study treatment until the first date of either objective disease progression or death due to any cause.

OS is defined as the time until death due to any cause.

ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.prior to progression or any further therapy.

Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1.

use EORTC QLQ-C30(version 3) questionnaire to evaluate the quality of life.

Rongjie Tao

Chief Physician

Shandong Cancer Hospital and Institute

BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.

A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.

Hernia

BP self-standing felt device

Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.

PR Parietene mesh device

preliminary results, doi:10.1088/0953-8984/20/47/474203

National Health Institute (ISS Istituto Superiore di Sanità), Viale Regina Elena 299

BP as a Super-light Mesh and as a New Fixation Device for General Surgery -DM108/2008-B

"BP as a Super-light Mesh and as a New Fixing Device for General, Emergency and Prosthetic Surgery. The BP Implantation Effects on Immunity System, on the Metabolism and on Sealing. Preliminary Experimentation of Small Feasibility Study"

bio-compatibility of Buckypaper implanted in a lumbar scar by evaluation of liver function by SGOT(Serum Glutamic Oxaloacetic Transaminase), SGPT(Serum Glutamic PyruvateTransaminase), GGT(gamma glutamyl transferase), ALP(alkaline phosphatase) and fractionated bilirubin, PT(Prothrombin Time), APTT/PTT(Activated partial thromboplastin time), Fibrinogen. The evaluation will be performed at the beginning of experimentation and at the sacrifice after 35 days and will be evaluated the difference (delta) before and after implantation of BP

We will investigate the effects of exposition to BP fragments on healthy tissues and CaCo2 cells (Cancer Colon cluster), MCF-7 (Michigan Cancer Foundation-7), a breast cancer cell line, and hSCs (healthy smooth-muscle cells) of thyroid artery.

bio-compatibility of Buckypaper implanted in a lumbar scar by evaluation of kidney by BUN and blood creatinine, and creatinine clearance. The evaluation will be performed at the beginning of experimentation and at the sacrifice after 35 days and will be evaluated the difference (delta) before and after implantation of BP

bio-compatibility of Buckypaper implanted in a lumbar scar by evaluation of marrow function by CBC(Complete Blood Count) formula, lymphocyte subpopulations, C-reactive protein, erythrocyte sedimentation rate. The evaluation will be performed at the beginning of experimentation and at the sacrifice after 35 days and will be evaluated the difference (delta) before and after implantation of BP

bio-adhesivity of the prosthetic material by the displacement in mm of the prosthesis from the implantation site

Massimo Chiaretti

Dr, PhD, MSc

University of Roma La Sapienza

University of Sannio

P Consentino Appialab Veterinary Reseach Labaratory

Catholic University of the Sacred Heart

E D'Amore Istituto Superiore Sanità

Antrodia cinnamomea and concomitant chemotherapy

Neoplasm

Functional Gastrointestinal Disorder

Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days

AC-Can

Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days

placebo

Division of Haematology and Oncology, Department of Internal Medicine and Traditional Chinese Medicine, Chang Gung Memorial Hospital - Kaohsiung Medical Center

Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy

Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy- a Double Blinded, Randomized, Placebo-controlled Trial

Post-chemotherapy nausea, vomiting and epigastragia, etc. including gastrointestinal symptom/sign without mention above.

Life science related questionnairs visit 4 times just before treatment, after intervention 7 days, 30 days and 90 days.

glutamate oxaloacetate transaminase/سرطان

Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib

BP as a Super-light Mesh and as a New Fixation Device for General Surgery -DM108/2008-B

Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم